• Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
  
• Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (from parent cell line).
  
• Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Phe (c.98C>T); ClinVar=VCV000017583; Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (from parent cell line).
  
• Mutation; HGNC; 8975; PIK3CA; Simple; p.Lys111Glu (c.331A>G); ClinVar=VCV000376482; Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; 11103; SMARCB1; Simple; c.362+1G>C; ClinVar=VCV000582116; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line).
  

PubMed=2566376
Keizer H.G., Schuurhuis G.J., Broxterman H.J., Lankelma J., Schoonen W.G.E.J., van Rijn J., Pinedo H.M., Joenje H.
Correlation of multidrug resistance with decreased drug accumulation, altered subcellular drug distribution, and increased P-glycoprotein expression in cultured SW-1573 human lung tumor cells.
Cancer Res. 49:2988-2993(1989)

PubMed=1974823
Baas F., Jongsma A.P.M., Broxterman H.J., Arceci R.J., Housman D.E., Scheffer G.L., Riethorst A., van Groenigen M., Nieuwint A.W.M., Joenje H.
Non-P-glycoprotein mediated mechanism for multidrug resistance precedes P-glycoprotein expression during in vitro selection for doxorubicin resistance in a human lung cancer cell line.
Cancer Res. 50:5392-5398(1990)

PubMed=1353703
Nieuwint A.W.M., Baas F., Wiegant J., Joenje H.
Cytogenetic alterations associated with P-glycoprotein- and non-P-glycoprotein-mediated multidrug resistance in SW-1573 human lung tumor cell lines.
Cancer Res. 52:4361-4371(1992)